A CLINICAL STUDY TO EVALUATE THE EFFICACY OF SHILODBHIDADI TAILA MATRA BASTI IN THE MANAGEMENT OF VATASHTHILA WITH SPECIAL REFERENCE TO BENIGN PROSTATIC HYPERPLASIA(BPH)

A CLINICAL STUDY TO EVALUATE EFFICACY OF SHILODBHIDADI TAILA MATRA BASTI IN THE MANAGEMENT OF VATASHTHILA WITH SPECIAL REFERENCE TO BENIGN PROSTATIC HYPERPLASIA(BPH)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/03/024091

Enrollment

Registered

2020-03-19

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: N401- Benign prostatic hyperplasia withlower urinary tract symptoms

Interventions

Intervention1: SHILODBHIDADI TAILA: SHILODBHIDADI TAILA MATRABASTI 72 ML FOR 7 DAYS OD AFTERFOOD Intervention2: SHILODBHIDADI TAILA: SHILODBHIDADI TAILA MATRA BASTI 72ML FOR 7 DAYS OD AFTER FOOD Inter

Eligibility

Inclusion criteria

Inclusion criteria: PATIENTS HAVING THE SIGNS AND SYMPTOMS OF VATASHTHILA (BPH)

Exclusion criteria

Exclusion criteria: PATIENTS BELOW 40 YRS OF AGE. SUFFERING FROM UROGENITAL DEFORMITIES AND ANY PELVIC PATHOLOGY. UNCONTROLLED HYPERTENSION AND DM. TUBERCULOSIS. PARALYSIS

Design outcomes

Primary

Measure	Time frame
SHILODBHIDADI TAILA MATRABASTI WILL BE EFFECTIVE IN THE MANAGEMENT OF VATASHTHILATimepoint: SHILODBHIDADI TAILA MATRABASTI WILL BE EFFECTIVE IN THE MANAGEMENT OF VATASHTHILA WITHIN 4 weeks	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDR ABHILASHA KORE

PARUL INSTITUTE OF AYURVED

abhilasha1214@gmail.com7507797467

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026